Surgical resection strategy and the influence of radicality on outcomes in oesophageal cancer

British Journal of Surgery

Volumn 101, Issue 5, 2014, Pages 511-517

  Davies, A R ^a,b,c,d   Sandhu, H ^a   Pillai, A ^a   Sinha, P ^a   Mattsson, F ^d   Forshaw, M J ^a   Gossage, J A ^a,d   Lagergren, J ^a,c,d   Allum, W H ^b   Mason, R C ^a,c,d  

^a ST THOMAS HOSPITAL   (United Kingdom)

^b ROYAL MARSDEN HOSPITAL   (United Kingdom)

^c KING'S COLLEGE LONDON   (United Kingdom)

^d KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOCARCINOMA; ADULT; AGED; ARTICLE; ESOPHAGUS RESECTION; ESOPHAGUS TUMOR; FEMALE; HUMAN; LOWER ESOPHAGUS SPHINCTER; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MALE; METHODOLOGY; MIDDLE AGED; MORTALITY; PROSPECTIVE STUDY; SQUAMOUS CELL CARCINOMA; TREATMENT OUTCOME; UNITED KINGDOM; VERY ELDERLY;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, SQUAMOUS CELL; ESOPHAGEAL NEOPLASMS; ESOPHAGECTOMY; ESOPHAGOGASTRIC JUNCTION; FEMALE; HOSPITAL MORTALITY; HUMANS; LONDON; LYMPH NODE EXCISION; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84896127550     PISSN: 00071323     EISSN: 13652168     Source Type: Journal    
DOI: 10.1002/bjs.9456     Document Type: Article

References (33)

1. Hulscher JB, van Sandick JW, de Boer AG, Wijnhoven BP, Tijssen JG, Fockens P, et al. Extended transthoracic resection compared with limited transhiatal resection for adenocarcinoma of the esophagus. N Engl J Med 2002; 347: 1662-1669.
2. Omloo JM, Lagarde SM, Hulscher JB, Reitsma JB, Fockens P, van Dekken H, et al. Extended transthoracic resection compared with limited transhiatal resection for adenocarcinoma of the mid/distal esophagus: five-year survival of a randomized clinical trial. Ann Surg 2007; 246: 992-1000.
3. Siewert JR, Stein HJ,. Classification of adenocarcinoma of the oesophagogastric junction. Br J Surg 1998; 85: 1457-1459.
4. Medical Research Council Oesophageal Cancer Working Group. Surgical resection with or without preoperative chemotherapy in oesophageal cancer: a randomised controlled trial. Lancet 2002; 359: 1727-1733.
5. Cunningham D, Allum WH, Stenning SP, Thompson JN, Van de Velde CJ, Nicolson M, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 2006; 355: 11-20.
6. Rice TW, Blackstone EH, Rusch VW,. 7th edition of the AJCC Cancer Staging Manual: esophagus and esophagogastric junction. Ann Surg Oncol 2010; 17: 1721-1724.
7. Mandard AM, Dalibard F, Mandard JC, Marnay J, Henry-Amar M, Petiot JF, et al. Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma. Clinicopathologic correlations. Cancer 1994; 73: 2680-2686.
8. Mapstone N., Dataset for the Histopathological Reporting of Oesophageal Carcinoma (2nd edn). Royal College of Pathologists: London, 2007.
9. Stiles BM, Nasar A, Mirza FA, Lee PC, Paul S, Port JL, et al. Worldwide Oesophageal Cancer Collaboration guidelines for lymphadenectomy predict survival following neoadjuvant therapy. Eur J Cardiothorac Surg 2012; 42: 659-664.
10. Schoenfeld D., Residuals for the proportional hazards regression model. Biometrika 1982; 69: 239-241.
11. Bonenkamp JJ, Hermans J, Sasako M, van de Velde CJ, Welvaart K, Songun I, et al. Extended lymph-node dissection for gastric cancer. N Engl J Med 1999; 340: 908-914.
12. Cuschieri A, Fayers P, Fielding J, Craven J, Bancewicz J, Joypaul V, et al. Postoperative morbidity and mortality after D1 and D2 resections for gastric cancer: preliminary results of the MRC randomised controlled surgical trial. The Surgical Cooperative Group. Lancet 1996; 347: 995-999.
13. Yamashita H, Katai H, Morita S, Saka M, Taniguchi H, Fukagawa T,. Optimal extent of lymph node dissection for Siewert type II esophagogastric junction carcinoma. Ann Surg 2011; 254: 274-280.
14. Sujendran V, Wheeler J, Baron R, Warren BF, Maynard N,. Effect of neoadjuvant chemotherapy on circumferential margin positivity and its impact on prognosis in patients with resectable oesophageal cancer. Br J Surg 2008; 95: 191-194.
15. Matsuyama J, Doki Y, Yasuda T, Miyata H, Fujiwara Y, Takiguchi S, et al. The effect of neoadjuvant chemotherapy on lymph node micrometastases in squamous cell carcinomas of the thoracic esophagus. Surgery 2007; 141: 570-580.
16. Chang AC, Ji H, Birkmeyer NJ, Orringer MB, Birkmeyer JD,. Outcomes after transhiatal and transthoracic esophagectomy for cancer. Ann Thorac Surg 2008; 85: 424-429.
17. Gockel I, Heckhoff S, Messow CM, Kneist W, Junginger T,. Transhiatal and transthoracic resection in adenocarcinoma of the esophagus: does the operative approach have an influence on the long-term prognosis? World J Surg Oncol 2005; 3: 40.
18. Goldminc M, Maddern G, Le Prise E, Meunier B, Campion JP, Launois B,. Oesophagectomy by a transhiatal approach or thoracotomy: a prospective randomized trial. Br J Surg 1993; 80: 367-370.
19. Chu KM, Law SY, Fok M, Wong J,. A prospective randomized comparison of transhiatal and transthoracic resection for lower-third esophageal carcinoma. Am J Surg 1997; 174: 320-324.
20. Jacobi CA, Zieren HU, Müller JM, Pichlmaier H,. Surgical therapy of esophageal carcinoma: the influence of surgical approach and esophageal resection on cardiopulmonary function. Eur J Cardiothorac Surg 1997; 11: 32-37.
21. Hulscher JB, Tijssen JG, Obertop H, van Lanschot JJ,. Transthoracic versus transhiatal resection for carcinoma of the esophagus: a meta-analysis. Ann Thorac Surg 2001; 72: 306-313.
22. Rindani R, Martin CJ, Cox MR,. Transhiatal versus Ivor Lewis oesophagectomy: is there a difference? Aust N Z J Surg 1999; 69: 187-194.
23. Boshier PR, Anderson O, Hanna GB,. Transthoracic versus transhiatal esophagectomy for the treatment of esophagogastric cancer: a meta-analysis. Ann Surg 2011; 254: 894-906.
24. Blencowe NS, Strong S, McNair AG, Brookes ST, Crosby T, Griffin SM, et al. Reporting of short-term clinical outcomes after esophagectomy: a systematic review. Ann Surg 2012; 255: 658-666.
25. Altorki NK, Zhou XK, Stiles B, Port JL, Paul S, Lee PC, et al. Total number of resected lymph nodes predicts survival in esophageal cancer. Ann Surg 2008; 248: 221-226.
26. Peyre CG, Hagen JA, DeMeester SR, Altorki NK, Ancona E, Griffin SM, et al. The number of lymph nodes removed predicts survival in esophageal cancer: an international study on the impact of extent of surgical resection. Ann Surg 2008; 248: 549-556.
27. Chen YJ, Schultheiss TE, Wong JY, Kernstine KH,. Impact of the number of resected and involved lymph nodes on esophageal cancer survival. J Surg Oncol 2009; 100: 127-132.
28. Twine CP, Lewis WG, Morgan MA, Chan D, Clark GW, Havard T, et al. The assessment of prognosis of surgically resected oesophageal cancer is dependent on the number of lymph nodes examined pathologically. Histopathology 2009; 55: 46-52.
29. Peyre CG, Hagen JA, DeMeester SR, Van Lanschot JJ, Holscher A, Law S, et al. Predicting systemic disease in patients with esophageal cancer after esophagectomy: a multinational study on the significance of the number of involved lymph nodes. Ann Surg 2008; 248: 979-985.
30. Li SH, Wang Z, Liu XY, Liu FY, Sun ZY, Xue H,. Lymph node micrometastasis: a predictor of early tumor relapse after complete resection of histologically node-negative esophageal cancer. Surg Today 2007; 37: 1047-1052.
31. Scheepers JJ, van der Peet DL, Veenhof AA, Cuesta MA,. Influence of circumferential resection margin on prognosis in distal esophageal and gastroesophageal cancer approached through the transhiatal route. Dis Esophagus 2009; 22: 42-48.
32. Salih T, Jose P, Mehta SP, Mirza A, Udall G, Pritchard SA, et al. Prognostic significance of cancer within 1 mm of the circumferential resection margin in oesophageal cancer patients following neo-adjuvant chemotherapy. Eur J Cardiothorac Surg 2013; 43: 562-567.
33. Izon AS, Jose P, Hayden JD, Grabsch HI,. Significant variation of resected meso-esophageal tissue volume in two-stage subtotal esophagectomy specimens: a retrospective morphometric study. Ann Surg Oncol 2013; 20: 788-797.